Protector effect of α-thalassaemia on cholecystitis and cholecystectomy in sickle cell disease

<p><b>Objectives:</b> Cholecystitis is one of the complications of symptomatic cholelithiasis responsible for high levels of morbidity of sickle cell disease (SCD) patients. Here, we investigated the possible protective role of single gene deletions of α-thalassaemia in the occurrence of cholelithiasis and cholecystitis in SCD patients, as well as the cholecystectomy requirements.</p> <p><b>Methods:</b> The α-globin genotype was determined in 83 SCD patients using the multiplex-polymerase chain reaction and compared with clinical events.</p> <p><b>Results:</b> Overall, in 23% of patients, -α^3.7 deletion was found. α-Thalassaemia concomitant to SCD was an independent protective factor to cholecystitis (OR = 0.07; 95% CI: 0.01–0.66; <i>p</i> = 0.020) and cholecystectomy requirement (OR = 0.14; 95% CI: 0.03–0.60; <i>p</i> = 0.008). The risk of cholelithiasis was not affected by the α-thalassaemia concomitance.</p> <p><b>Conclusions:</b> To the best our knowledge, our study is the first to show the protective effect of α-thalassaemia on cholecystitis and cholecystectomy requirements in SCD, which may be due to an improved splenic function.</p

Immunophenotypic identification and chraracterization of pediatric tumor samples.

<p>In panel A, an illustrating example of the gating strategy and bivariate dot plot combinations used for the identification of CD45− tumor cells, CD45− residual stromal cells (e.g. endothelial cells and mesenquimal cells) and infiltrating hematopoietic cells (e.g. neutrophils, B and T cells) is shown. In turn, in panels B to J the immunophenotypic profile of CD45− tumor cells from a neuroblastoma (panels B and H), a PNET (panels C and I) and a rhabdomyossarcoma (panels D and J) tumor are shown together with representative pictures of the histophathological and immunohistochemical profiles of the same tumors stained with hematoxilin & eosin plus cromogranin (neuroblastoma cells in panel E), CD99 (PNET cells in panel F) and _(nu)myogenin (rhabdomyossarcoma cells in panel G).</p

Comparison between multiparameter flow cytometry (MFC) and histopathology plus immunohistochemistry (IH) as regards identification of infiltration by neoplastic cells versus normal/reactive cells.

<p>All 8 samples were obtained from pediatric cancer patients, but they were all negative for the presence of tumor cells by conventional diagnostic approaches. LL: lymphoblastic lymphoma; PNET- primitive neuroectodermal tumor.</p

Pattern of antigen expression by tumor cells from different diagnostic categories of pediatric solid tumors.

<p>−: negative; +lo :low expression levels/cells; +: positive; +hi: strong expression levels/cells.</p><p>Both CD7 and CD8 were systematically negative in all tumors analyzed.</p>*<p>The only ganglioneuroblastoma tumor analyzed showed a similar profile but it contained two distinct populations which differed on CD56, CD9 and CD81 expression, in the absence of CD117.</p> <p>CD271 was only partially present in one neuroblastoma tumor.</p>§<p>% of positive cells only among positive case.</p